The global manufacturing company is getting some qualified support from analysts. A Macquarie report says Amcor is a market leader in pharmaceutical flexibles after its acquisition of Alcan and it has a strong legacy business in the medical and hospital industry segments. It says the Alcan acquisition brought important technology gains. “The business has performed strongly over the past few years, with solid sales growth from innovation and significant improvements in return for the four acquired American plants. Growth in [pharmaceuticals operations] is more likely to be organically driven as Amcor is already a clear market leader.” Macquarie has an “outperform” rating and a price target of $7.79. The stock is an earnings multiple of 14.3 times and an unfranked dividend yield of 5 per cent. Deutsche Bank has a “buy” on the stock.